Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

39.31B

Market cap39.31B

Price-Earnings ratio

68.02

Price-Earnings ratio68.02

Dividend yield

—

Dividend yield—

Average volume

990.95K

Average volume990.95K

High today

$297.25

High today$297.25

Low today

$284.38

Low today$284.38

Open price

$288.58

Open price$288.58

Volume

751.52K

Volume751.52K

52 Week high

$495.55

52 Week high$495.55

52 Week low

$284.19

52 Week low$284.19

Stock Snapshot

Alnylam Pharmaceuticals(ALNY) stock is priced at $297.25, giving the company a market capitalization of 39.31B. It carries a P/E multiple of 68.02.

During the trading session on 2026-05-19, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $297.25 and a low of $284.38. At a current price of $297.25, the stock is +4.5% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 751.52K, compared to an average daily volume of 990.95K.

The stock's 52-week range extends from a low of $284.19 to a high of $495.55.

ALNY News

Simply Wall St 10h

How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam Investors - simplywall.st

...

TipRanks 1d

Alnylam initiated with a Buy at Citi

Citi initiated coverage of Alnylam (ALNY) with a Buy rating and $380 price target The expanded launch of Amvuttra for ATTR-CM has “no doubt been impressive,” sa...

Simply Wall St 4d

A Look At Alnylam Pharmaceuticals Valuation As HELIOS B Data And TTR Guidance Reassure Investors

For investors watching Alnylam Pharmaceuticals (ALNY), the latest HELIOS-B Phase 3 analyses of vutrisiran and reaffirmed transthyretin, or TTR, franchise revenu...

Analyst ratings

70%

of 30 ratings

Buy

70%

Hold

30%

Sell

More ALNY News

TipRanks 5d

Alnylam’s New Hypertension Combo Study Could Reshape Its Long-Term Value

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, shar...

TipRanks 5d

Alnylam Steps Into Obesity Drug Race With New ALN-2232 Trial

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, shar...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Eli Lilly

Vertex Pharmaceuticals

Netflix

Taiwan Semiconductor Manu…

Novo Nordisk

Meta Platforms

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.